Anja Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 41)
Anja Health logo

Anja Health

EmergingHealthcare

General

Affordable cord blood and tissue banking with FDA-registered storage for broader stem cell access; $4.62M from Seven Seven Six and YC at $1.8M revenue competing with CBR for expectant parent insurance market.

AI VisibilityBeta
Overall Score
C41
Category Rank
#352 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
46
Gemini
45

About

Anja Health is a San Jose-based cord blood and cord tissue banking company that makes stem cell preservation from newborn births accessible and affordable — providing nationwide FDA-registered collection and storage of umbilical cord blood and cord tissue that contain hematopoietic stem cells and mesenchymal stem cells, which may be used in future treatments for blood disorders, immune conditions, and emerging regenerative medicine applications. Founded in 2021 and backed by Alexis Ohanian's Seven Seven Six fund and Y Combinator with $4.62 million raised including a $2 million seed round in May 2024, Anja Health achieved $1.8 million in revenue as of December 2024.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

41
Overall Score
90
#352
Category Rank
#2
73
AI Consensus
83
stable
Trend
stable
39
ChatGPT
92
46
Perplexity
93
45
Gemini
89
35
Claude
96
41
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.